[ASAP] Selective DYRK1A Inhibitor for the Treatment of Neurodegenerative Diseases: Alzheimer, Parkinson, Huntington, and Down Syndrome

ACS Medicinal Chemistry LettersDOI: 10.1021/acsmedchemlett.0c00346

Source: ACS Medicinal Chemistry Letters - July 9, 2020 Category: Chemistry Authors: Robert B. Kargbo* Source Type: research